Azmi, Asfar S.

Immune evasion in cancer: mechanistic basis and therapeutic strategies

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,625

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 185

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

Azmi, A. S., Aboukameel, A., Banerjee, S., Wang, Z., Mohammad, M., Wu, J., Wang, S., Yang, D., Philip, P. A., Sarkar, F. H., et al. (2010) · European Journal of Cancer

Cancer-related Molecular PathwaysPancreatic and Hepatic Oncology Research

Cited by 67

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 48

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer

Sexton, R., Mahdi, Z., Chaudhury, R., Beydoun, R., Aboukameel, A., Khan, H. Y., Baloglu, E., Senapedis, W., Landesman, Y., Tesfaye, A., et al. (2019) · International Journal of Molecular Sciences

Nuclear Structure and FunctionDrug Transport and Resistance Mechanisms

Cited by 47